Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Christian talking at 4th Global Liver Congress

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Apr 22, 2021 1:50pm

79 Views

Post# 33046028

RE:RE:Christian talking at 4th Global Liver Congress

Who knows, maybe the FDA was doing TH a favor by delaying their start of the phase III knowing they were going to come out with new guidelines.

qwerty22 wrote:
The regulators are talking at this meeting too. Maybe something new???

It looks like a more holistic conference (science, industry, regulatory) than some of the others.

qwerty22 wrote:

https://www.global-engage.com/event/nash/

You can access the agenda by clicking on 'read the agenda'. (I registered with totally made-up details)

Here is the blurb on Christian's presentation.

CHRISTIAN MARSOLAIS

Senior Vice President and Chief Medical Officer, Theratechnologies, Canada

Treating NASH through a unique mode of action with tesamorelin

Tesamorelin is a Growth Hormone Releasing Hormone (GHRH) Analog indicated

for the treatment of visceral adipose tissue accumulation in People Living with HIV. Tesamorelin,with over 10 years of real-life data,has a well-established safety and efficacy profile.It has a significant impact on the accumulation of ectopic fat, reduction of visceral adipose tissue, reduction of fat accumulation inthe muscle (trunkmusclegroup) and decrease of liver fat accumulation while increasing lean body mass. Based on transcriptomic analysis of liver biopsies, tesamorelin was shown to have significant impact on oxidative phosphorylation, inflammatory makers related to fibrosis, and improvements in gene expression related to favorable hepatocellular carcinoma prognosis. Tesamorelin is currently being evaluated as an investigational treatment for all people living with nonalcoholic steatohepatitis (NASH).